Abstract
OnabotulinumtoxinA (OnabotA) appears to be an effective prophylactic treatment for chronic migraine (CM), but its use in patients with episodic migraine (EM) has been little explored. We set out to assess the clinical efficacy of OnabotA in a real-life setting, focusing particularly on EM patients. This is a longitudinal, prospective, single-center analysis of 115 migraine patients [70 with CM, 21 with low-frequency EM (LFEM), and 24 with high-frequency EM (HFEM)] who received OnabotA in routine clinical practice in 2005–2015. In this study, the dosage regimen, the number of headaches, impact on quality of life (HIT-6 impact test) and the adverse events were among the parameters assessed. OnabotA treatment significantly reduced the number of headaches experienced by CM and EM patients, also increasing the number of responders (> 50% reduction in headache days). The quality of life of EM patients improved significantly, reducing the HIT-6 scores in both LFEM and HFEM patients. Adverse events were reported in 40% of patients, always mild and transient. OnabotA is an effective and safe prophylactic treatment for migraine in routine clinical practice. It significantly improves a patients’ quality of life, particularly that of those suffering from CM and HFEM.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.